AKINETON Drug Patent Profile
Which patents cover Akineton, and when can generic versions of Akineton launch?
Akineton is a drug marketed by Abbvie and is included in two NDAs.
The generic ingredient in AKINETON is biperiden hydrochloride. There are two drug master file entries for this compound. Additional details are available on the biperiden hydrochloride profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for AKINETON?
- What are the global sales for AKINETON?
- What is Average Wholesale Price for AKINETON?
Summary for AKINETON
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 41 |
| Clinical Trials: | 3 |
| Patent Applications: | 4,268 |
| DailyMed Link: | AKINETON at DailyMed |
Recent Clinical Trials for AKINETON
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Ministry of Health, Brazil | Phase 3 |
| Hospital Sirio-Libanes | Phase 3 |
| PROADI-SUS | Phase 3 |
US Patents and Regulatory Information for AKINETON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | AKINETON | biperiden lactate | INJECTABLE;INJECTION | 012418-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Abbvie | AKINETON | biperiden hydrochloride | TABLET;ORAL | 012003-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
